l General Information |
Product Name | Belinostat |
General description | Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. |
Synonym | N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; PXD-101; NSC726630;PX-105684 |
Purity | ≥98%(HPLC) | CAS Number | 414864-00-9 |
Formula | C15H14N2O4S | Molecular Weight | 318.347 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Light pink solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase. |
Application | 1. Antineoplastic Agents 2. Histone Deacetylase Inhibitors |
l Packaging & Storage |
Packaging | 10mg; 50mg; 250mg |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
